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Please note: 
Within this document you find general information about the drug of interest and the indication it is 
intended to be used for. Further we have included full text publications and conference abstracts of 
phase III trials, assessing the safety and efficacy of the drugs of interest. 
At the very end of each chapter we have provided a table containing the prioritization criteria and a 
drop-down field to apply the provided criteria. 
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Introduction 
As part of the project „Horizon Scanning in Oncology“ (further information can be found here: 
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie), 9 information sources are scanned 
frequently to identify emerging anticancer drugs. 
Every 3 months, these anticancer therapies are filtered (i.e. in most cases defined as availability of 
phase III results; for orphan drugs also phase II) to identify drugs at/around the same time as the 
accompanying drug licensing decisions of the EMA.  
An expert panel consisting of oncologists and pharmacists then applies 5 prioritisation criteria to 
elicit those anti-cancer therapies which might be associated with either a considerable impact on 
financial resources or a substantial health benefit.  
For the 25th prioritisation (December 2015), 11 drugs were filtered out of 199 identified and were 
sent to prioritisation. Of these, 3 drugs were ranked as ‘highly relevant’ by the expert panel, 8 as 
‘relevant’ and none as ‘not relevant’. For ‘highly relevant’ drugs, further information including, for 
example, abstracts of phase III studies and licensing status is contained in this document. 
The summary judgements of the expert panel for all prioritised drugs are provided in the following 
table. 
 
No Filtered Drugs – 25
th
 prioritisation 4
th
 quarter 2015 Overall category 
1. 
Paclitaxel (Abraxane®, Ebetaxel®, ABI-007) in chemotherapy-naïve 
patients with metastatic melanoma 
Relevant 
2. 
Ipilimumab (Yervoy®, MDX-010) as adjuvant therapy for high risk stage 
III melanoma 
Relevant 
3. 
Nivolumab (BMS-936558 / MDX1106 / ONO4538) versus everolimus in 
previously treated patients with advanced renal cell carcinoma 
Relevant 
4. 
Cabozantinib (CometriqTM) versus everolimus for previously treated 
patients with advanced renal cell carcinoma 
Relevant 
5. 
Daratumumab (DarzalexTM) as a monotherapy in patients with ≥3 lines 
of prior therapy or double refractory multiple myeloma 
Relevant 
6. 
Ixazomib (MLN9708, Ninlaro®) in combination with lenalidomide and 
dexamethasone for patients with relapsed and/or refractory multiple 
myeloma 
Highly relevant 
7. 
Pembrolizumab (Keytruda®, MK-3475) versus docetaxel in previously-
treated participants with non-small cell lung cancer 
Highly relevant 
8. 
Nedaplatin (Aqupla) plus docetaxel versus cisplatin plus docetaxel for 
advanced or relapsed squamous cell carcinoma of the lung 
Relevant 
9. 
Alectinib (ALECENSA®) for anaplastic lymphoma kinase (ALK)-
positive, metastatic non-small cell lung cancer (NSCLC) 
Relevant 
10. 
Ofatumumab (Arzerra) maintenance versus observation in relapsed 
chronic lymphocytic leukaemia 
Highly relevant 
11. 
Erlotinib (Tarceva®) in combination with bevacizumab for maintenance 
therapy in patients with unresectable metastatic colorectal cancer 
Relevant 
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1 Multiple myeloma  
1.1 Ixazomib (MLN9708, Ninlaro®) in combination with 
lenalidomide and dexamethasone for patients with relapsed 
and/or refractory multiple myeloma  
Overview 
Drug Description oral proteasome inhibitor 
Patient Indication 
Ixazomib in combination with lenalidomide and dexamethasone for the 
treatment of patients with multiple myeloma who have received at least 
one prior therapy. 
Incidence in 
Austria 
627 newly diagnosed per year (2012), 5.6 /100,000/year 
Approval 
status for 
this 
indication 
EMA - 
FDA 
11/2015: ixazomib in combination with lenalidomide and dexamethasone 
for the treatment of patients with multiple myeloma who have received at 
least one prior therapy. 
 
Phase III results: - 
Other Sources: FDA 
www.accessdata.fda.gov/drugsatfda_docs/label/2015/208462lbl.pdf (page 15-18) 
 
2 Lung cancer 
2.1 Pembrolizumab (Keytruda®, MK-3475) versus docetaxel in 
previously-treated participants with non-small cell lung cancer  
Overview 
Drug Description a human programmed death receptor-1 (PD-1)-blocking antibody 
Patient Indication 
Pembrolizumab versus docetaxel in previously-treated participants with 
non-small cell lung cancer 
Incidence in 
Austria 
4,573 newly diagnosed per year (2012), 30.5 /100,000/year 
Approval 
status for 
EMA - 
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this 
indication FDA 
10/2015: patients with advanced (metastatic) non-small cell lung cancer 
(NSCLC) whose disease has progressed after other treatments and with 
tumors that express a protein called PD-L1. 
 
Phase III results:  
The Lancet, Published Online December 19, 2015 (Herbst et al.): “Pembrolizumab versus 
docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-
010): a randomised controlled trial” 
 
Background 
Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a 
need for effective treatments for progressive disease. We assessed the efficacy of pembrolizumab for 
patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer. 
 
Methods 
We did this randomised, open-label, phase 2/3 study at 202 academic medical centres in 24 countries. 
Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of 
tumour cells were randomly assigned (1:1:1) in blocks of six per stratum with an interactive voice-
response system to receive pembrolizumab 2 mg/kg, pembrolizumab 10 mg/kg, or docetaxel 75 
mg/m
2
 every 3 weeks. The primary endpoints were overall survival and progression-free survival both 
in the total population and in patients with PD-L1 expression on at least 50% of tumour cells. We used 
a threshold for significance of p<0·00825 (one-sided) for the analysis of overall survival and a 
threshold of p<0·001 for progression-free survival. This trial is registered at ClinicalTrials.gov, number 
NCT01905657. 
 
Findings 
Between Aug 28, 2013, and Feb 27, 2015, we enrolled 1034 patients: 345 allocated to pembrolizumab 
2 mg/kg, 346 allocated to pembrolizumab 10 mg/kg, and 343 allocated to docetaxel. By Sept 30, 2015, 
521 patients had died. In the total population, median overall survival was 10·4 months with 
pembrolizumab 2 mg/kg, 12·7 months with pembrolizumab 10 mg/kg, and 8·5 months with docetaxel. 
Overall survival was significantly longer for pembrolizumab 2 mg/kg versus docetaxel (hazard ratio 
[HR] 0·71, 95% CI 0·58–0·88; p=0·0008) and for pembrolizumab 10 mg/kg versus docetaxel (0·61, 
0·49–0·75; p<0·0001). Median progression-free survival was 3·9 months with pembrolizumab 2 
mg/kg, 4·0 months with pembrolizumab 10 mg/kg, and 4·0 months with docetaxel, with no significant 
difference for pembrolizumab 2 mg/kg versus docetaxel (0·88, 0·74–1·05; p=0·07) or for 
pembrolizumab 10 mg/kg versus docetaxel (HR 0·79, 95% CI 0·66–0·94; p=0·004). Among patients 
with at least 50% of tumour cells expressing PD-L1, overall survival was significantly longer with 
pembrolizumab 2 mg/kg than with docetaxel (median 14·9 months vs 8·2 months; HR 0·54, 95% CI 
0·38–0·77; p=0·0002) and with pembrolizumab 10 mg/kg than with docetaxel (17·3 months vs 8·2 
months; 0·50, 0·36–0·70; p<0·0001). Likewise, for this patient population, progression-free survival 
was significantly longer with pembrolizumab 2 mg/kg than with docetaxel (median 5·0 months vs 4·1 
months; HR 0·59, 95% CI 0·44–0·78; p=0·0001) and with pembrolizumab 10 mg/kg than with 
docetaxel (5·2 months vs 4·1 months; 0·59, 0·45–0·78; p<0·0001). Grade 3–5 treatment-related 
adverse events were less common with pembrolizumab than with docetaxel (43 [13%] of 339 patients 
given 2 mg/kg, 55 [16%] of 343 given 10 mg/kg, and 109 [35%] of 309 given docetaxel). 
 
Interpretation 
Pembrolizumab prolongs overall survival and has a favourable benefit-to-risk profile in patients with 
previously treated, PD-L1-positive, advanced non-small-cell lung cancer. These data establish 
pembrolizumab as a new treatment option for this population and validate the use of PD-L1 selection. 
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3 Leukemia 
3.1 Ofatumumab (Arzerra) maintenance versus observation in 
relapsed chronic lymphocytic leukaemia  
Overview 
Drug Description CD20-directed cytolytic monoclonal antibody 
Patient Indication 
maintenance treatment versus observation for patients in remission after 
re-induction treatment for relapsed chronic lymphocytic leukaemia 
Incidence in 
Austria 
1,083 newly diagnosed per year (2012), 8.1 /100,000/year 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
 
Phase III results:  
The Lancet (2015) Volume 16, Issue: 13 Pages 1370–1379 (H J van Oers et al.): “Ofatumumab 
maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-
label, multicentre, randomised phase 3 study” 
 PDF-file: ofatumumab_leukemia_H J van Oers_2015_LANCET.pdf 
 
Background 
Ofatumumab is a human anti-CD20 monoclonal antibody that has proven efficacy as monotherapy in 
refractory chronic lymphocytic leukaemia. We assessed the efficacy and safety of ofatumumab 
maintenance treatment versus observation for patients in remission after re-induction treatment for 
relapsed chronic lymphocytic leukaemia. 
 
Methods 
This open-label, multicentre, randomised phase 3 study enrolled patients aged 18 years or older from 
130 centres in 24 countries who had chronic lymphocytic leukaemia in complete or partial remission 
after second-line or third-line treatment. Eligible patients had a WHO performance status of 0–2, had a 
response assessment within the previous 3 months, did not have refractory disease, autoimmune 
haemolytic anaemia requiring treatment, chronic or active infection requiring treatment, and had not 
previously received maintenance treatment or autologous or allogeneic stem-cell transplant. Using a 
randomisation list generated by a central computerised system and an interactive voice recognition 
system, we randomly assigned (1:1) patients to receive ofatumumab (300 mg followed by 1000 mg 1 
week later and every 8 weeks for up to 2 years) or undergo observation. Randomisation was stratified 
by number and type of previous treatment and remission status after induction treatment (block size of 
four). Treatment assignment was open label. The primary endpoint was investigator-assessed 
progression-free survival in the intention-to-treat population. We report the results of a prespecified 
interim analysis after two-thirds of the planned study events (disease progression or death) had 
happened. This trial is closed to accrual but follow-up is ongoing. This trial is registered with 
ClinicalTrials.gov, number NCT00802737. 
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Findings 
Between May 6, 2010, and June 19, 2014, we enrolled 474 patients: 238 patients were randomly 
assigned to receive ofatumumab maintenance treatment and 236 to undergo observation. One (<1%) 
patient in the ofatumumab group did not receive the allocated intervention (withdrawal of consent). 
The median follow-up was 19·1 months (IQR 10·3–28·8). Progression-free survival was improved in 
patients assigned to the ofatumumab group (29·4 months, 95% CI 26·2–34·2) compared with those 
assigned to observation (15·2 months, 11·8–18·8; hazard ratio 0·50, 95% CI 0·38–0·66; p<0·0001). 
The most common grade 3 or higher adverse events up to 60 days after last treatment were 
neutropenia (56 [24%] of 237 patients in the ofatumumab group vs 23 [10%] of 237 in the observation 
group) and infections (31 [13%] vs 20 [8%]). 20 (8%) of 237 patients in the ofatumumab group and 
three (1%) of 237 patients in the observation group had adverse events that led to permanent 
discontinuation of treatment. Up to 60 days after last treatment, two deaths related to adverse events 
occurred in the ofatumumab treatment group and five deaths related to adverse events occurred in the 
observation group; no deaths were attributed to the study drug. 
 
Interpretation 
These data are important for the development of optimum maintenance strategies in patients with 
relapsed chronic lymphocytic leukaemia, notably in the present era of targeted drugs, many of which 
are to be used until progression. 
 
 
